Philadelphia-negative classical myeloproliferative neoplasms

critical concepts and management recommendations from European leukemiaNet

Tiziano Barbui, Giovanni Barosi, Gunnar Birgegard, Francisco Cervantes, Guido Finazzi, Martin Griesshammer, Claire Harrison, Hans Carl Hasselbalch, Rudiger Hehlmann, Ronald Hoffman, Jean Jacques Kiladjian, Nicolaus Kröger, Ruben Mesa, Mary F. McMullin, Animesh Pardanani, Francesco Passamonti, Alessandro M. Vannucchi, Andreas Reiter, Richard T. Silver, Srdan Verstovsek & 1 others Ayalew Tefferi

Research output: Contribution to journalReview article

502 Citations (Scopus)

Abstract

We present a review of critical concepts and produce recommendations on the management of Philadelphia-negative classical myeloproliferative neoplasms, including monitoring, response definition, first- and second-line therapy, and therapy for special issues. Key questions were selected according the criterion of clinical relevance. Statements were produced using a Delphi process, and two consensus conferences involving a panel of 21 experts appointed by the European LeukemiaNet (ELN) were convened. Patients with polycythemia vera (PV) and essential thrombocythemia (ET) should be defined as high risk if age is greater than 60 years or there is a history of previous thrombosis. Risk stratification in primary myelofibrosis (PMF) should start with the International Prognostic Scoring System (IPSS) for newly diagnosed patients and dynamic IPSS for patients being seen during their disease course, with the addition of cytogenetics evaluation and transfusion status. High-risk patients with PV should be managed with phlebotomy, low-dose aspirin, and cytoreduction, with either hydroxyurea or interferon at any age. High-risk patients with ET should be managed with cytoreduction, using hydroxyurea at any age. Monitoring response in PV and ET should use the ELN clinicohematologic criteria. Corticosteroids, androgens, erythropoiesis-stimulating agents, and immunomodulators are recommended to treat anemia of PMF, whereas hydroxyurea is the first-line treatment of PMF-associated splenomegaly. Indications for splenectomy include symptomatic portal hypertension, drug-refractory painful splenomegaly, and frequent RBC transfusions. The risk of allogeneic stem-cell transplantation-related complications is justified in transplantation-eligible patients whose median survival time is expected to be less than 5 years.

Original languageEnglish (US)
Pages (from-to)761-770
Number of pages10
JournalJournal of Clinical Oncology
Volume29
Issue number6
DOIs
StatePublished - Feb 20 2011
Externally publishedYes

Fingerprint

Essential Thrombocythemia
Polycythemia Vera
Primary Myelofibrosis
Hydroxyurea
Neoplasms
Splenomegaly
Hematinics
Phlebotomy
Immunologic Factors
Portal Hypertension
Stem Cell Transplantation
Splenectomy
Cytogenetics
Interferons
Androgens
Aspirin
Anemia
Adrenal Cortex Hormones
Thrombosis
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Philadelphia-negative classical myeloproliferative neoplasms : critical concepts and management recommendations from European leukemiaNet. / Barbui, Tiziano; Barosi, Giovanni; Birgegard, Gunnar; Cervantes, Francisco; Finazzi, Guido; Griesshammer, Martin; Harrison, Claire; Hasselbalch, Hans Carl; Hehlmann, Rudiger; Hoffman, Ronald; Kiladjian, Jean Jacques; Kröger, Nicolaus; Mesa, Ruben; McMullin, Mary F.; Pardanani, Animesh; Passamonti, Francesco; Vannucchi, Alessandro M.; Reiter, Andreas; Silver, Richard T.; Verstovsek, Srdan; Tefferi, Ayalew.

In: Journal of Clinical Oncology, Vol. 29, No. 6, 20.02.2011, p. 761-770.

Research output: Contribution to journalReview article

Barbui, T, Barosi, G, Birgegard, G, Cervantes, F, Finazzi, G, Griesshammer, M, Harrison, C, Hasselbalch, HC, Hehlmann, R, Hoffman, R, Kiladjian, JJ, Kröger, N, Mesa, R, McMullin, MF, Pardanani, A, Passamonti, F, Vannucchi, AM, Reiter, A, Silver, RT, Verstovsek, S & Tefferi, A 2011, 'Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European leukemiaNet', Journal of Clinical Oncology, vol. 29, no. 6, pp. 761-770. https://doi.org/10.1200/JCO.2010.31.8436
Barbui, Tiziano ; Barosi, Giovanni ; Birgegard, Gunnar ; Cervantes, Francisco ; Finazzi, Guido ; Griesshammer, Martin ; Harrison, Claire ; Hasselbalch, Hans Carl ; Hehlmann, Rudiger ; Hoffman, Ronald ; Kiladjian, Jean Jacques ; Kröger, Nicolaus ; Mesa, Ruben ; McMullin, Mary F. ; Pardanani, Animesh ; Passamonti, Francesco ; Vannucchi, Alessandro M. ; Reiter, Andreas ; Silver, Richard T. ; Verstovsek, Srdan ; Tefferi, Ayalew. / Philadelphia-negative classical myeloproliferative neoplasms : critical concepts and management recommendations from European leukemiaNet. In: Journal of Clinical Oncology. 2011 ; Vol. 29, No. 6. pp. 761-770.
@article{4328d525fe604aea8c4da1dc3c659c0c,
title = "Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European leukemiaNet",
abstract = "We present a review of critical concepts and produce recommendations on the management of Philadelphia-negative classical myeloproliferative neoplasms, including monitoring, response definition, first- and second-line therapy, and therapy for special issues. Key questions were selected according the criterion of clinical relevance. Statements were produced using a Delphi process, and two consensus conferences involving a panel of 21 experts appointed by the European LeukemiaNet (ELN) were convened. Patients with polycythemia vera (PV) and essential thrombocythemia (ET) should be defined as high risk if age is greater than 60 years or there is a history of previous thrombosis. Risk stratification in primary myelofibrosis (PMF) should start with the International Prognostic Scoring System (IPSS) for newly diagnosed patients and dynamic IPSS for patients being seen during their disease course, with the addition of cytogenetics evaluation and transfusion status. High-risk patients with PV should be managed with phlebotomy, low-dose aspirin, and cytoreduction, with either hydroxyurea or interferon at any age. High-risk patients with ET should be managed with cytoreduction, using hydroxyurea at any age. Monitoring response in PV and ET should use the ELN clinicohematologic criteria. Corticosteroids, androgens, erythropoiesis-stimulating agents, and immunomodulators are recommended to treat anemia of PMF, whereas hydroxyurea is the first-line treatment of PMF-associated splenomegaly. Indications for splenectomy include symptomatic portal hypertension, drug-refractory painful splenomegaly, and frequent RBC transfusions. The risk of allogeneic stem-cell transplantation-related complications is justified in transplantation-eligible patients whose median survival time is expected to be less than 5 years.",
author = "Tiziano Barbui and Giovanni Barosi and Gunnar Birgegard and Francisco Cervantes and Guido Finazzi and Martin Griesshammer and Claire Harrison and Hasselbalch, {Hans Carl} and Rudiger Hehlmann and Ronald Hoffman and Kiladjian, {Jean Jacques} and Nicolaus Kr{\"o}ger and Ruben Mesa and McMullin, {Mary F.} and Animesh Pardanani and Francesco Passamonti and Vannucchi, {Alessandro M.} and Andreas Reiter and Silver, {Richard T.} and Srdan Verstovsek and Ayalew Tefferi",
year = "2011",
month = "2",
day = "20",
doi = "10.1200/JCO.2010.31.8436",
language = "English (US)",
volume = "29",
pages = "761--770",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Philadelphia-negative classical myeloproliferative neoplasms

T2 - critical concepts and management recommendations from European leukemiaNet

AU - Barbui, Tiziano

AU - Barosi, Giovanni

AU - Birgegard, Gunnar

AU - Cervantes, Francisco

AU - Finazzi, Guido

AU - Griesshammer, Martin

AU - Harrison, Claire

AU - Hasselbalch, Hans Carl

AU - Hehlmann, Rudiger

AU - Hoffman, Ronald

AU - Kiladjian, Jean Jacques

AU - Kröger, Nicolaus

AU - Mesa, Ruben

AU - McMullin, Mary F.

AU - Pardanani, Animesh

AU - Passamonti, Francesco

AU - Vannucchi, Alessandro M.

AU - Reiter, Andreas

AU - Silver, Richard T.

AU - Verstovsek, Srdan

AU - Tefferi, Ayalew

PY - 2011/2/20

Y1 - 2011/2/20

N2 - We present a review of critical concepts and produce recommendations on the management of Philadelphia-negative classical myeloproliferative neoplasms, including monitoring, response definition, first- and second-line therapy, and therapy for special issues. Key questions were selected according the criterion of clinical relevance. Statements were produced using a Delphi process, and two consensus conferences involving a panel of 21 experts appointed by the European LeukemiaNet (ELN) were convened. Patients with polycythemia vera (PV) and essential thrombocythemia (ET) should be defined as high risk if age is greater than 60 years or there is a history of previous thrombosis. Risk stratification in primary myelofibrosis (PMF) should start with the International Prognostic Scoring System (IPSS) for newly diagnosed patients and dynamic IPSS for patients being seen during their disease course, with the addition of cytogenetics evaluation and transfusion status. High-risk patients with PV should be managed with phlebotomy, low-dose aspirin, and cytoreduction, with either hydroxyurea or interferon at any age. High-risk patients with ET should be managed with cytoreduction, using hydroxyurea at any age. Monitoring response in PV and ET should use the ELN clinicohematologic criteria. Corticosteroids, androgens, erythropoiesis-stimulating agents, and immunomodulators are recommended to treat anemia of PMF, whereas hydroxyurea is the first-line treatment of PMF-associated splenomegaly. Indications for splenectomy include symptomatic portal hypertension, drug-refractory painful splenomegaly, and frequent RBC transfusions. The risk of allogeneic stem-cell transplantation-related complications is justified in transplantation-eligible patients whose median survival time is expected to be less than 5 years.

AB - We present a review of critical concepts and produce recommendations on the management of Philadelphia-negative classical myeloproliferative neoplasms, including monitoring, response definition, first- and second-line therapy, and therapy for special issues. Key questions were selected according the criterion of clinical relevance. Statements were produced using a Delphi process, and two consensus conferences involving a panel of 21 experts appointed by the European LeukemiaNet (ELN) were convened. Patients with polycythemia vera (PV) and essential thrombocythemia (ET) should be defined as high risk if age is greater than 60 years or there is a history of previous thrombosis. Risk stratification in primary myelofibrosis (PMF) should start with the International Prognostic Scoring System (IPSS) for newly diagnosed patients and dynamic IPSS for patients being seen during their disease course, with the addition of cytogenetics evaluation and transfusion status. High-risk patients with PV should be managed with phlebotomy, low-dose aspirin, and cytoreduction, with either hydroxyurea or interferon at any age. High-risk patients with ET should be managed with cytoreduction, using hydroxyurea at any age. Monitoring response in PV and ET should use the ELN clinicohematologic criteria. Corticosteroids, androgens, erythropoiesis-stimulating agents, and immunomodulators are recommended to treat anemia of PMF, whereas hydroxyurea is the first-line treatment of PMF-associated splenomegaly. Indications for splenectomy include symptomatic portal hypertension, drug-refractory painful splenomegaly, and frequent RBC transfusions. The risk of allogeneic stem-cell transplantation-related complications is justified in transplantation-eligible patients whose median survival time is expected to be less than 5 years.

UR - http://www.scopus.com/inward/record.url?scp=79551491928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551491928&partnerID=8YFLogxK

U2 - 10.1200/JCO.2010.31.8436

DO - 10.1200/JCO.2010.31.8436

M3 - Review article

VL - 29

SP - 761

EP - 770

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -